Search

everythinglearnresearchcommunity

for

Search:↓

Catatonia can be a rare sign of lupus, needing careful diagnosis and treatment.

Patients with central centrifugal cicatricial alopecia often have higher rates of metabolic, autoimmune, and atopic conditions, as well as anxiety and depression.

People with hidradenitis suppurativa have a higher risk of heart attacks and strokes.

Use specific tools to measure quality of life in alopecia areata patients and improve future treatments.

Alopecia areata severity is influenced by factors like long disease duration, relapses, treatment response, and mental health, leading to the creation of a new severity measurement tool.

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

Patients with central centrifugal cicatricial alopecia benefit from shared decision-making with their doctors.

The document explains how to claim CME credit by diagnosing and treating hair loss conditions in two patient cases.

Rhupus is a complex syndrome that combines rheumatoid arthritis and lupus, making diagnosis challenging.

Model improves accuracy in predicting hair loss effects.

Ulcerative colitis involves immune activation, chronic inflammation, and metabolic issues, some of which persist even during remission.

The decision board effectively helps lupus nephritis patients in Brazil choose treatments by clearly presenting options and side effects.

The SAALIQ is a reliable tool for measuring the impact of alopecia areata on Spanish-speaking patients' quality of life.

Inconsistent safety reporting in chronic back pain trials risks patient safety and decision-making.

High-frequency ultrasonography helps diagnose and manage hair and nail disorders safely and effectively.

The document's conclusion cannot be provided because the content is not accessible.

The Alopecia Areata Assessment Tool (ALTO) effectively identifies alopecia areata from other hair loss types but needs more validation.

Systemic lupus erythematosus is a complex autoimmune disease mainly affecting women, with varied symptoms and unknown exact cause.

DLQI is a reasonable quality-of-life measure for alopecia patients, but more research is needed.

LiPADI is a useful tool for monitoring the severity and treatment of lichen planus.

Clear definitions and strategies are needed to manage long-term COVID-19 symptoms effectively.

VESALT improves alopecia areata assessment by including non-scalp areas and is reliable and user-friendly.

The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.

The model helps predict uranium levels in human hair from drinking contaminated water, offering an alternative to urine tests.

The document concludes that a new questionnaire to assess mental health in alopecia patients shows low rates of seeking mental health services and support groups.

The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.

The 2012 SLICC criteria provide an updated method for classifying Systemic Lupus Erythematosus.

Health care providers should address the emotional challenges of SLE patients with comprehensive care.

Different people show different symptoms for genetic diseases because of how sensitive their bodies are to small changes in important factors.